Safety and Efficacy of Very Low Levels of LDL Cholesterol

This prespecified analysis assesses the safety and clinical efficacy of achieving a very low (<30 mg/dL) level of low-density lipoprotein cholesterol at 1 month in patients with acute coronary syndrome using data from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial.

Read the full article here

Related Articles